Efficacy of Dupilumab for Controlling Severe Atopic Dermatitis in a Patient with Hyper-IgE Syndrome

J Clin Immunol. 2020 Feb;40(2):418-420. doi: 10.1007/s10875-020-00751-4. Epub 2020 Jan 28.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Anti-Allergic Agents / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Dermatitis, Atopic / drug therapy*
  • Female
  • Humans
  • Job Syndrome / diagnosis*
  • Middle Aged
  • Receptors, Interleukin-4 / immunology
  • Treatment Outcome

Substances

  • Anti-Allergic Agents
  • Antibodies, Monoclonal, Humanized
  • Receptors, Interleukin-4
  • dupilumab